Information  X 
Enter a valid email address

Venture Life Group (VLG)

  Print      Mail a friend

Wednesday 01 April, 2020

Venture Life Group

Notice of Results

RNS Number : 4554I
Venture Life Group PLC
01 April 2020
 

1 April 2020

 

Venture Life Group plc

("Venture Life" or the "Company")

Notice of Results

Venture Life (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market, today announces that it will announce its preliminary results for the year ended 31 December 2019 on Thursday 9 April 2020.

For further information please contact: 

Venture Life Group PLC

+44 (0) 1344 578 004

Jerry Randall, Chief Executive Officer


Andrew Waters, Chief Financial Officer

 


Cenkos Securities plc (Nominated Adviser and broker)

+44 (0) 207 397 8900

 

Stephen Keys / Cameron MacRitchie (Corporate Finance)

Russell Kerr / Michael Johnson (Sales)


Alma PR

[email protected]  or

+44 (0) 203 405 0208

Helena Bogle/Hilary Buchanan/Kieran Breheny


 

About Venture Life (   www.venture-life.com  )

Venture Life is an international consumer self-care company focused on acquiring, developing, manufacturing and commercialising products for the global self-care market. With operations in the UK, Italy and the Netherlands, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, , medical devices for dermatology, oral care, women's intimate healthcare and proctology, and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK and the Netherlands these are supplied direct by the company, elsewhere they are supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the OTC consumer products sector, primarily in respect of medical devices.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORZFLFBBZLBBBE

a d v e r t i s e m e n t